Mentari Therapeutics Inc. (MTRI)
MTRI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-06-30, https://www.sec.gov/Archives/edgar/data/1728328/000121390025090210/0001213900-25-090210-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | MTRI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001728328 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | BC |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.9M |
| Net income | -$8.2M |
| Operating income | Not in SEC XBRL data |
| Net margin | -165.1% |
| Operating margin | Operating income not reported |
| Revenue growth | +7.5% |
| Cash | $11.1M |
| Total assets | $15.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 212.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued." | 10-Q 2026-11-03 |
| Cash and burn | $1.1M cash; operating cash flow -$2.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2026-10-30 |
| Reverse splits, 3 years | 2; latest 1-for-10 on 2026-11-05 | Source 2026-11-05 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-04-03 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-09-18 |
| Auditor | CBIZ CPAs P.C., New York, New York, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-06-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1.3M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-09-30 | Not filed | -$2.3M | -$1.1M | $1.1M | No debt tags | Needs four quarters | 10-Q 2026-11-03 |
| Q4 2026 2026-06-30 | Not filed | -$5.8M | -$3.0M | $2.2M | No debt tags | Needs four quarters | 10-K 2026-09-09 |
| Q3 2026 2026-03-31 | Not filed | -$3.0M | -$1.7M | $5.2M | No debt tags | Needs four quarters | 10-Q 2026-05-06 |
| Q2 2026 2025-12-31 | $820K | -$2.0M | -$2.1M | $7.0M | No debt tags | $4.5M | 10-Q 2026-02-11 |
| Q1 2026 2025-09-30 | $1.1M | -$1.7M | -$1.9M | $9.3M | No debt tags | $4.8M | 10-Q 2025-11-06 |
| Q4 2025 2025-06-30 | $1.3M | $4.7M | -$2.1M | $10.7M | No debt tags | $4.9M | 10-K 2025-09-23 |
| Q3 2025 2025-03-31 | $1.3M | -$2.1M | -$1.7M | $4.7M | No debt tags | $4.9M | 10-Q 2025-05-12 |
| Q2 2025 2024-12-31 | $1.1M | -$2.6M | -$2.5M | $3.4M | No debt tags | $4.8M | 10-Q 2026-02-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-10-28 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-09-09 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy DEFINITIVE ADDITIONAL MATERIALS | DEFA14A | 2025-11-03 |
Source: SEC EDGAR submissions feed, 537 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +19.5% |
| 1 month | +39.8% |
| 3 months | +30.1% |
| Year to date | +75.5% |
| 1 year | +2.8% |
| From 52-week high | 0.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SPTX | Seaport Therapeutics Inc. | $19.12 | -4.30% | $1.0B |
| ANRO | Alto Neuroscience Inc. | $27.12 | -8.19% | $1.1B |
| HROW | Harrow Inc. | $29.09 | -3.42% | $1.1B |
| CYRX | CryoPort Inc. | $19.80 | -0.45% | $1.0B |
| MLTX | MoonLake Immunotherapeutics | $11.73 | -6.16% | $998.3M |
| SVRA | Savara Inc. | $4.46 | -3.77% | $985.1M |
| JBIO | Jade Biosciences Inc. | $15.34 | -4.99% | $975.3M |
| VSTM | Verastem Inc. | $7.70 | -5.87% | $970.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier